When discussing controversial figures like Martin Shkreli, public opinion often polarizes between vilification and defense. The question "is Martin Shkreli really evil?" has sparked intense debate, with critics accusing him of price-gouging and prioritizing profits over public health, while supporters see him as a misunderstood entrepreneur. Let's delve into both sides of the argument to form a balanced perspective.

Martin Shkreli's reputation was largely forged during his time as the CEO of Turing Pharmaceuticals. In 2015, he infamously raised the price of Daraprim, a lifesaving drug used to treat HIV and cancer patients, from $13.50 to $750 per pill. This decision drew widespread outrage and branded him as one of the most hated people in America. But is this the full story, or is there more nuance to Shkreli's character and actions?

Shkreli's Background and Business Acumen
Before scrutinizing Shkreli's actions as a businessman, it's essential to consider his background. Born into a low-income family in New York, Shkreli was self-taught in programming and finance. His intellectual prowess secured him a full scholarship to college, where he honed his analytical skills and developed a reputation for forthrightness, regardless of its political incorrectness.

Shkreli's first foray into entrepreneurship, MSMB Capital Management, was founded in 2009. Although it eventually closed, Shkreli's ability to generate substantial returns for investors earned him a formidable reputation on Wall Street. In 2011, he founded Retrophin, a drug development company focused on rare diseases. Ironically, it was while working at Retrophin that Shkreli began his foray into price-gouging, albeit at a smaller scale than his later actions at Turing.
Price Gouging: Seinfelds or Serious Business Strategy?

Shkreli's critics point to his dramatic drug price increases as evidence of his ulterior motives. In the case of Daraprim, Turing acquired the drug's license for just $55,000. For many, hiking the price by over 5000% seemed driven by nothing more than greed. Indeed, Shkreli's notoriously smug demeanor when discussing this price increase only further fuelled the fire of public opinion against him.
However, some argue that this approach is purely business strategy. Pharmaceuticals follow a free market model that, for all its flaws, allows for risky drug development and the potential for significant returns. This cycle is self-sustaining; investors fund research, and pharmaceutical companies recoup costs (and turn a profit) through drug sales.
Shkreli's Role in the Broader Pharmaceutical Industry

Shkreli's vocal criticism of the pharmaceutical industry's price gouging, self-admittedly for bipartisan and traction purposes, highlights the broader issue of drug pricing. After acquiring Daraprim, Turing reinvested the profits into research and development, with a stated aim of creating more affordable generic alternatives. Even so, Shkreli's tactics remain controversial.
Moreover, Shkreli's personal history sheds light on his motivations. Diagnosed with Thalassemia at age 4, Shkreli is all too familiar with the plight of rare disease sufferers. His outspokenness and takedowns of political correctness, though often derided as arrogance, sometimes manifest as an unapologetic stance towards improving medical care and access to pharmaceuticals.
The Legal Case Against Shkreli

In late 2015, Shkreli was indicted on charges of securities fraud and conspiracy for his actions at MSMB Capital Management. In 2017, he was found guilty on two counts of securities fraud and one count of conspiracy to commit securities fraud. Sentenced to seven years in prison, many see this legal result as confirmation of Shkreli's wrongdoing and manipulation.
Supporters counter that Shkreli's actions were misguided and egregious but not criminal. They argue that his mousey demeanor and limited social skills didn't help his case and contributed to a negative public image that fed into his legal downfall.






In conclusion, the debate surrounding Martin Shkreli's character is as complex as the man himself. His actions ave undeniably harmed many, but they also reflect deep-rooted issues in the pharmaceutical industry. To better understand Shkreli, one must view him through a prism that accounts for his background, intellect, and unorthodox approach to business. Only then can we formulate a balanced opinion on his legacy and whether, indeed, Martin Shkreli is 'really evil'."